MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results — David A. Sallman (2022) | RDL Network
MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver
David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver
Discussion(0)
No comments yet. Be the first to comment.